sofosbuvir

Product Details:

Sofosbuvir 400 MG
MEDIVAC INTERNATIONAL

Sofosbuvir is an antiviral medicine that is used to treat chronic hepatitis C in adults and children who are at least 12 years old or who weigh at least 77 pounds (35 kilograms). Sofosbuvir must be given in combination with other antiviral medications (usually ribavirin with or without peginterferon...

Usual Adult Dose for:

• Chronic Hepatitis C

Usual Pediatric Dose for:

• Chronic Hepatitis C

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Chronic Hepatitis C

400 mg orally once a day

Recommended Regimen and Duration of Therapy:
-Genotype 1 or 4: Sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks
-Genotype 2: Sofosbuvir and ribavirin for 12 weeks
-Genotype 3: Sofosbuvir and ribavirin for 24 weeks
-Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first)

Comments:
-Genotype 1, 4: This regimen is recommended for therapy-naive patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
-Genotype 2, 3: Both regimens are recommended for therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
-Therapy-experienced patients have failed an interferon-based regimen (with or without ribavirin).
-The dose recommendations for genotype 1, 2, 3, or 4 should be followed for HCV/HIV-1-coinfected patients.
-The manufacturer product information should be consulted for ribavirin dose recommendations; with genotype 1 or 4, the manufacturer product information for peginterferon alfa should also be consulted for dose recommendations.
-Sofosbuvir and ribavirin for 24 weeks can be considered for patients with genotype 1 infection who cannot use an interferon-based regimen; treatment decision should be guided by benefit/risk assessment for the individual patient.
-The regimen for patients with hepatocellular carcinoma awaiting liver transplantation is recommended to prevent posttransplant HCV reinfection.